Vimarsana
Biggest News Aggregation in the World

Page 4 - Plasma Cell News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Plasma Cell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Plasma Cell Today - Breaking & Trending Today

ASCO | OriCell Therapeutics Announces Oral Presentation at 2022 ASCO Annual Meeting Detailing Results from Phase I POLARIS Study of OriCAR-017 - Vimarsana News

ASCO | OriCell Therapeutics Announces Oral Presentation at 2022 ASCO Annual Meeting Detailing Results from Phase I POLARIS Study of OriCAR-017

/PRNewswire/ -- OriCell Therapeutics Co., Ltd (OriCell), a leading innovative biopharmaceutical company pioneering novel oncology cell therapies for the unmet...

Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting CAR-T GC012F for Relapsed/Refractory Multiple Myeloma at 2022 ASCO Annual Meeting - Vimarsana News

Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting CAR-T GC012F for Relapsed/Refractory Multiple Myeloma at 2022 ASCO Annual Meeting

/PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to...

Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting CAR-T GC012F for Relapsed/Refractory Multiple Myeloma at 2022 ASCO Annual Meeting - Vimarsana News

Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting CAR-T GC012F for Relapsed/Refractory Multiple Myeloma at 2022 ASCO Annual Meeting

/PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to...

Arcellx Provides Business Updates and Reports First Quarter 2022 Financial Results - Vimarsana News

Arcellx Provides Business Updates and Reports First Quarter 2022 Financial Results

-- First patient dosed in the Phase 1 clinical trial evaluating ACLX-001 utilizing groundbreaking ARC-SparX technology in relapsed or refractory m...

Gracell Biotechnologies Announces Details of Oral Abstract Presentation at 2022 ASCO Annual Meeting - Vimarsana News

Gracell Biotechnologies Announces Details of Oral Abstract Presentation at 2022 ASCO Annual Meeting

/PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to...